Elanix Biotechnologies Launches Adherence App for GYNrepair® Women’s Intimate Health Cream. Specifically designed for use on the intimate external mucosa, GYNrepair® cream soothes the feeling of discomfort, twinges and dryness. GYNrepair® cream contains a proprietary Cell Free Protein Complex (CFPC®), including various proteins, such as collagen and fibronectin, and is perfume-free.
“Smartphone apps are revolutionizing delivery of healthcare, particularly in the field of adherence. Our user-friendly app will help women schedule recommended application of GYNrepair® cream into their busy lives. Elanix will continue to explore how additional features on the app can provide benefits to our customers,” stated Tomas Svoboda, CEO of Elanix Biotechnologies. “We have developed the app to support commercialization expansion for GYNrepair® cream and provide an easy to use, direct interface to our customers. This interaction with our customers, we believe, will help drive commercial success for the product.”
*Disclaimer – The app does not store personal data and is not intended for diagnostic purposes.
About Women’s Intimate Health
Approximately 10-15% of all women seeking gynecological help suffer from intimate discomfort, twinges and dryness that result from several conditions, including vestibulodynia, vulvodynia, pudendal nerve entrapment and persistent genital arousal disorder. Recommended treatment varies considerably from medications and creams to physical therapy, stress management and holistic approaches.
REPAIR-A is dedicated to the development and marketing of progenitor cell based CFPC® creams. Since its founding in 2007, REPAIR-A has marketed a CFPC® cream based on 30 years of animal progenitor cell research and development that originated from Professor Lee Ann Laurent-Applegate. Elanix Biotechnologies acquired REPAIR-A in September 2016 to add a commercially-ready, synergistic progenitor cell-based product portfolio, enabling early revenue generation.
Elanix Biotechnologies AG (FRA: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working human cell banks with vast quantities of cells.
Elanix is headquartered in Nyon, Switzerland, with its registered office in Potsdam, Germany, and listed on the Frankfurt Stock Exchange under the symbol ELN. For more information and updates, visit www.elanixbiotechnologies.com.
Disclaimer / Forward-looking statements:
This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.